Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease

Background:

- The availability of high quality, clinically annotated patient samples is crucial for
the study of biologic factors that influence the natural history of viral related
malignancies, malignancies occurring in the setting of HIV, and Castleman disease

- Comprehensive genomic sequence of viral-associated malignancies, malignancies occurring
in the setting of HIV, tumors hypothesized to be caused by endogenous retroviruses, and
Castleman disease may identify diagnostic or prognostic disease signatures, and
recurrent driver alterations that interact with viral factors, and may identify targets
for new therapies

- Comparison of transcriptomes and genomes between cancers or Castleman disease from HIV+
and HIV- individuals might identify novel non-human sequences that could potentially
suggest the presence of transcripts from hitherto undiscovered oncogenic viral agents

Objective:

-The primary objective of this protocol is to support molecular investigation of viral
associated malignancies, malignancies occurring in the setting of HIV or other
immunodeficiencies, and Castleman disease, by accrual of high quality, clinically annotated
tissue from such patients as well as patients with tumors that may serve as appropriate
controls.

Eligibility:

- Age >18 years

- HIV or other acquired immunodeficiency and cancer or

- Viral-associated cancer or

- HIV-negative with cancer that commonly occurs in people with HIV or

- Kaposi sarcoma herpes virus (KSHV)-associated malignancy or related diseases, such as
Multicentric Castleman Disease or

- Idiopathic Castleman disease or

- Tumors that are hypothesized to be caused by endogenous retroviruses

Design:

- Samples will be processed using project specific collection and processing protocols.

- Collection of non-tumor specimens will generally be performed to obtain germ-line
genetic material. The results between tumor and normal DNA will be analyzed to identify
the somatic changes present in the cancer tissues.

- Alterations to be evaluated may include: detection of chromosomal changes, such as, but
not limited to, amplification, deletions, loss of heterozygosity, translocations, etc.;
as well as expression profiling and detection of transcripts resulting from
translocations and mutations, including single nucleotide variants, insertions,
deletions, etc.

- Multiple forms of project specific analyses may be performed, including evaluation of
polymorphisms, mutations, gene expression and clinical pathologic correlation based on
project specific statistical and bioinformatics plans.

- Alterations may also be analyzed within the context of biological pathways and systems
biology being evaluated in a given project.

- INCLUSION CRITERIA:

Patients with one or more of the following:

- HIV or other acquired immunodeficiency and cancer

- Viral-associated cancer or cancer hypothesized to be caused by a virus

- HIV-negative patients with cancer that commonly occurs in people with HIV

- KSHV-associated malignancy or related diseases, such as Multicentric Castleman Disease

- A malignancy hypothesized to be caused by an endogenous retrovirus

- Idiopathic Castleman disease

Cancer diagnoses will be confirmed by the NCI Laboratory of Pathology. A biopsy will be
collected if sufficient archival tissue is not available.

- Age >18 years.

- ECOG performance status less than or equal to 2 (Karnofsky greater than or equal to
.60%) if biopsy to be performed is solely for the purposes of this protocol. Any ECOG
performance status will be allowed if biopsy required for patient care or another NIH
protocol that allows lower performance status or if enrollment on this protocol is
only for the purposes of studying tissue that has already been collected.

- Patients must have signed or be willing to sign an IRB-approved informed consent
document that permits the use of the tumor and other samples for genomic-based
molecular characterization projects. Telephone consent for use of archival tissue or
tissue collected on another protocol or standard patient care will be permitted.

- Co-enrollment on other HAMB, NCI, or NIH protocols is allowed

EXCLUSION CRITERIA:

- Inability to provide informed consent.

- Pregnancy: Pregnant women will not be allowed to participate in this study because
there is not a potential benefit.